Full Press Release Details
Protocol version 8.0 posted on Novavax.com Pediatric Vaccination After 2 doses: functional immune responses 2.4 - 4x higher than in adults, including against Delta and Omicron April 2021 First dose June 2021 Completed enrollment October 2021 Completed blinded crossover Expected 1Q 2022 Complete regulatory filing for pediatric indication (12 - 17 years) Study Design 2,248 adolescents (12 - 17 years) Randomized 2:1 Initial Findings 18 2022 NOVAVAX.
The Company does not undertake to update or revise any forward - looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law . Novavax TM (and all associated logos) and NanoFlu TM are trademarks of Novavax, Inc . Matrix - M TM is a trademark of Novavax AB . 3 2022 NOVAVAX.
Forward - looking statements are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance . Current results may not be predictive of future results . You should not place considerable reliance on forward - looking statements which speak only as of the date hereof .
These risks and uncertainties include challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities ; difficulty obtaining scarce raw materials and supplies ; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways ; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities ; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10 - K for the year ended December 31 , 2020 and subsequent Quarterly Reports on Form 10 - Q, as filed with the Securities and Exchange Commission, which are available at www . sec . gov and www . novavax . com .
Forward - looking statements may generally contain words such as "believe," "may," "could," "will," "possible," "can," "estimate," "continue," "ongoing," "consider," "intend," "indicate," "plan," "project," "expect," "should," "would," or "assume" or variations of such words or other words with similar meanings . Novavax cautions that these forward - looking statements are subject to numerous assumptions, risks and uncertainties that change over time and may cause actual results to differ materially from the results discussed in the forward - looking statements .